Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02856568
Title Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mayo Clinic
Indications

cholangiocarcinoma

Therapies

Cisplatin + Gemcitabine + Ricolinostat

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.